Pfizer (UKEX:PFE) Cyclically Adjusted Revenue per Share: ₴517.95 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:PFE Pfizer Inc UKEX:PFE
73 GF Score
Price ₴1,014.00
GF Value ₴968.27
! 8 Warning Signs
View Full Analysis

What is Pfizer Cyclically Adjusted Revenue per Share?

Pfizer UKEX:PFE 73 Cyclically Adjusted Revenue per Share is ₴517.95 as of Jun. 2026. GuruFocus rates UKEX:PFE with a GF Score™ of 73/100 and a GF Value™ of ₴968.27. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pfizer's adjusted revenue per share for the three months ended in Jun. 2026 was ₴117.558. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₴517.95 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pfizer's average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pfizer was 13.90% per year. The lowest was -0.10% per year. And the median was 5.20% per year.

As of today (2026-09-14), Pfizer's current stock price is ₴1014.00. Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₴517.95. Pfizer's Cyclically Adjusted PS Ratio of today is 1.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 3.99.


Pfizer  (UKEX:PFE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pfizer's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1014.00/517.95
=1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 3.99.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pfizer Cyclically Adjusted Revenue per Share Related Terms


Pfizer Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pfizer's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cyclically Adjusted Revenue per Share Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 426.72 445.66 488.67

Pfizer Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 498.63 478.74 488.67 440.19 517.95

UKEX:PFE vs GILD, BMY, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PS Ratio falls into.


UKEX:PFE
73GF Score
Pfizer Inc UKEX:PFE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pfizer's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=117.558/333.9520*333.9520
=117.558

Current CPI (Jun. 2026) = 333.9520.

Pfizer Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 94.525 241.428 130.750
201612 99.380 241.432 137.464
201703 93.479 243.801 128.045
201706 95.194 244.955 129.780
201709 97.138 246.819 131.430
201712 100.751 246.524 136.482
201803 94.954 249.554 127.067
201806 100.821 251.989 133.614
201809 98.998 252.439 130.965
201812 8.703 251.233 11.568
201903 101.666 254.202 133.561
201906 104.211 256.143 135.867
201909 100.029 256.759 130.102
201912 14.588 256.974 18.958
202003 80.052 258.115 103.572
202006 78.230 257.797 101.340
202009 81.302 260.280 104.314
202012 89.937 260.474 115.308
202103 114.249 264.877 144.043
202106 148.327 271.696 182.314
202109 187.088 274.310 227.766
202112 184.171 278.802 220.602
202203 198.600 287.504 230.685
202206 216.435 296.311 243.929
202209 176.429 296.808 198.508
202212 194.969 296.797 219.377
202303 143.837 301.836 159.142
202306 101.451 305.109 111.042
202309 106.491 307.789 115.543
202312 114.030 306.746 124.144
202403 116.379 312.332 124.435
202406 103.921 314.175 110.463
202409 138.267 315.301 146.446
202412 138.808 315.605 146.877
202503 107.038 319.799 111.775
202506 114.438 322.561 118.479
202509 129.884 324.800 133.544
202512 136.735 324.054 140.911
202603 112.361 330.213 113.633
202606 117.558 333.952 117.558

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₴517.95 mean?
Pfizer (UKEX:PFE) has a Cyclically Adjusted Revenue per Share of ₴517.95 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors.
Is Pfizer's Cyclically Adjusted Revenue per Share too high?
Pfizer's current Cyclically Adjusted Revenue per Share is ₴517.95. Overall, Pfizer has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Cyclically Adjusted Revenue per Share compare to GILD and BMY?
Pfizer's Cyclically Adjusted Revenue per Share of ₴517.95 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors. Pfizer's current Cyclically Adjusted Revenue per Share is ₴517.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Pfizer (UKEX:PFE) has a current Cyclically Adjusted Revenue per Share of ₴517.95. The stock's GF Value™ is ₴968.27, compared to a current price of ₴1,014.00 — trading 4.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₴517.95. Pfizer's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pfizer (UKEX:PFE), the current Cyclically Adjusted Revenue per Share is ₴517.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (UKEX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be overvalued. The current stock price of ₴1,014.00 is trading 4.7% above its estimated GF Value™ of ₴968.27.

Key valuation signals for UKEX:PFE:

  • Cyclically Adjusted Revenue per Share: ₴517.95
  • GF Value™: ₴968.27 vs. price of ₴1,014.00 (4.7% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the UKEX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
73GF Score

Get the complete analysis for UKEX:PFE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴1,014.00
Price
₴968.27
GF Value